Insmed Incorporated

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing first-in-class therapies to transform the lives of patients facing serious and rare diseases. Headquartered in Bridgewater, New Jersey, USA, the company maintains offices and research facilities across the United States, Europe, and Japan.

The company's portfolio focuses on rare, neutrophil-mediated, and infectious pulmonary diseases, leveraging proprietary liposomal technology for targeted inhaled therapies. Key commercial products include ARIKAYCE® (amikacin liposome inhalation suspension), approved for refractory nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in the U.S., Europe, and Japan. Another commercial product is BRINSUPRI® (brensocatib). Insmed's pipeline features brensocatib in Phase 3 for bronchiectasis, treprostinil palmitil inhalation powder (TPIP) in Phase 3 for pulmonary hypertension associated with interstitial lung disease, and other candidates for various respiratory and rare conditions.

Led by CEO Will Lewis, Insmed has recently reported positive topline results from its Phase 3b ENCORE study of ARIKAYCE in MAC lung disease in March 2026. The company also announced first-quarter 2026 revenues of $306.0 million, with BRINSUPRI contributing $207.9 million and ARIKAYCE $98.1 million. Insmed has been recognized as a top employer in the biopharmaceutical industry, including being named the No. 1 Science Top Employer for five consecutive years. The company currently holds a market capitalization of approximately $20-21 billion.